Polymer Capital Management (HK)’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
Other funds holding MLTX
Polymer Capital Management (HK)'s MLTX Position: Q3 2026 in Review
Polymer Capital Management (HK) increased its MoonLake Immunotherapeutics (MLTX) stake by 90% in Q3 2026, buying an estimated $1.48M and bringing the position to 190,739 shares worth $2.23M. The position accounts for 0.21% of the portfolio, ranked #83.
Polymer Capital Management (HK) first reported a position in MLTX in Q2 2026 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold MLTX as of Q3 2026.
- Polymer Capital Management (HK) held 190,739 shares of MoonLake Immunotherapeutics worth $2.23M as of Q3 2026.
- Polymer Capital Management (HK) bought 90,276 MoonLake Immunotherapeutics shares in Q3 2026, an estimated $1.48M.
- MoonLake Immunotherapeutics made up 0.21% of Polymer Capital Management (HK)'s portfolio in Q3 2026, its #83 holding.
- Polymer Capital Management (HK) first reported a position in MoonLake Immunotherapeutics in Q2 2026 and has held it in 2 quarters since.
- 170 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2026.
Based on Polymer Capital Management (HK)'s 13F filing for Q3 2026, filed 13 Nov 2026.